Table of Contents Author Guidelines Submit a Manuscript
Infectious Diseases in Obstetrics and Gynecology
Volume 2015, Article ID 276851, 9 pages
http://dx.doi.org/10.1155/2015/276851
Research Article

Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya

1Department of Global Health, University of Washington, Seattle, WA 98104, USA
2Department of Nursing, University of Washington, Seattle, WA 98195, USA
3United States Centers for Disease Control and Prevention (CDC), Nairobi 00202, Kenya
4Center for Microbiology Research and Center for Clinical Research, Kenya Medical Research Institute, Nairobi 00202, Kenya
5Department of Obstetrics & Gynecology, Kenyatta National Hospital, Nairobi 00202, Kenya
6Department of Medicine, University of Washington, Seattle, WA 98195, USA
7Department of Epidemiology, University of Washington, Seattle, WA 98195, USA
8University of Texas Medical Branch, Galveston, TX 77555, USA

Received 22 October 2015; Revised 2 December 2015; Accepted 3 December 2015

Academic Editor: Faustino R. Perez-Lopez

Copyright © 2015 Jillian Pintye et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection, WHO, Geneva, Switzerland, 2013.
  2. World Health Organization, Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations, WHO Library Cataloguing-in-Publication Data, Geneva, Switzerland, 2014.
  3. National Institutes of Health, “Recommendations for use of antiretroviral drugs in pregnant hiv-1-infected women for maternal health and interventions to reduce perinatal hiv transmission in the united states,” 2012.
  4. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States, 2012.
  5. A. F. Tarantal, A. Castillo, J. E. Ekert, N. Bischofberger, and R. B. Martin, “Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta),” Journal of Acquired Immune Deficiency Syndromes, vol. 29, no. 3, pp. 207–220, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. K. K. Van Rompay, L. L. Brignolo, D. J. Meyer et al., “Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 5, pp. 1469–1487, 2004. View at Google Scholar
  7. K. K. A. Van Rompay, L. Durand-Gasselin, L. L. Brignolo et al., “Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 9, pp. 3144–3160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. A. B. Castillo, A. F. Tarantal, M. R. Watnik, and R. Bruce Martin, “Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta),” Journal of Orthopaedic Research, vol. 20, no. 6, pp. 1185–1189, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Wang, A. P. Kourtis, S. Ellington, J. Legardy-Williams, and M. Bulterys, “Safety of tenofovir during pregnancy for the mother and fetus: a systematic review,” Clinical Infectious Diseases, vol. 57, no. 12, pp. 1773–1781, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. B. H. Chi, M. Sinkala, F. Mbewe et al., “Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial,” The Lancet, vol. 370, no. 9600, pp. 1698–1705, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Arrivé, M.-L. Chaix, E. Nerrienet et al., “Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1,” AIDS, vol. 23, no. 7, pp. 825–833, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Arrive, M. L. Chaix, E. Nerrienet et al., “Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance,” AIDS, vol. 24, no. 16, pp. 2481–2488, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. P. M. Flynn, M. Mirochnick, D. E. Shapiro et al., “Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 12, pp. 5914–5922, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Kinai, S. Hosokawa, H. Gomibuchi, H. Gatanaga, Y. Kikuchi, and S. Oka, “Blunted fetal growth by tenofovir in late pregnancy,” AIDS, vol. 26, no. 16, pp. 2119–2120, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Q. Pan, L.-J. Mi, C. Bunchorntavakul et al., “Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis b virus infection by highly viremic pregnant women: a case series,” Digestive Diseases and Sciences, vol. 57, no. 9, pp. 2423–2429, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Beigi, L. Noguchi, T. Parsons et al., “Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy,” Journal of Infectious Diseases, vol. 204, no. 10, pp. 1527–1531, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Sabbatini, F. Prati, V. Borghi, A. Bedini, R. Esposito, and C. Mussini, “Congenital pyelectasis in children born from mothers on tenofovir containing therapy during pregnancy: report of two cases,” Infection, vol. 35, no. 6, pp. 474–476, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Nurutdinova, N. F. Onen, E. Hayes, K. Mondy, and E. T. Overton, “Adverse effects of tenofovir use in HIV-infected pregnant women and their infants,” Annals of Pharmacotherapy, vol. 42, no. 11, pp. 1581–1585, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Viganò, S. Mora, V. Giacomet et al., “In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers,” Antiviral Therapy, vol. 16, no. 8, pp. 1259–1266, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. A. P. H. Colbers, D. A. Hawkins, A. Gingelmaier et al., “The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women,” AIDS, vol. 27, no. 5, pp. 739–748, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. Antiretroviral Pregnancy Registry Steering Committee, Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2013, Registry Coordinating Center, Wilmington, NC, USA, 2013.
  22. N. R. Mugo, T. Hong, C. Celum et al., “Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial,” The Journal of the American Medical Association, vol. 312, no. 4, pp. 362–371, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. P. L. Vernazza, I. Graf, U. Sonnenberg-Schwan, M. Geit, and A. Meurer, “Preexposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child,” AIDS, vol. 25, no. 16, pp. 2005–2008, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. C. E. Ransom, Y. Huo, K. Patel et al., “Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy,” Journal of Acquired Immune Deficiency Syndromes, vol. 64, no. 4, pp. 374–381, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. G. K. Siberry, P. L. Williams, H. Mendez et al., “Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants,” AIDS, vol. 26, no. 9, pp. 1151–1159, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. D. M. Gibb, H. Kizito, E. C. Russell et al., “Pregnancy and infant outcomes among HIV-infected women taking long-term art with and without tenofovir in the DART trial,” PLoS Medicine, vol. 9, no. 5, Article ID e1001217, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. World Health Organization, WHO Child Growth Standards and the Identification of Severe Acute Malnutrition in Infants and Children: A Joint Statement by the World Health Organization and the United Nations Children's Fund, World Health Organization, Geneva, Switzerland, 2009.
  28. M. B. Duggan, “Anthropometry as a tool for measuring malnutrition: impact of the new WHO growth standards and reference,” Annals of Tropical Paediatrics, vol. 30, no. 1, pp. 1–17, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Keino, G. Plasqui, G. Ettyang, and B. van den Borne, “Determinants of stunting and overweight among young children and adolescents in sub-Saharan Africa,” Food and Nutrition Bulletin, vol. 35, no. 2, pp. 167–178, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. R. E. Black, C. G. Victora, S. P. Walker et al., “Maternal and child undernutrition and overweight in low-income and middle-income countries,” The Lancet, vol. 382, no. 9890, pp. 427–451, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Isanaka, C. Duggan, and W. W. Fawzi, “Patterns of postnatal growth in HIV-infected and HIV-exposed children,” Nutrition Reviews, vol. 67, no. 6, pp. 343–359, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. H. S. Kruger, “Maternal anthropometry and pregnancy outcomes: a proposal for the monitoring of pregnancy weight gain in outpatient clinics in South Africa,” Curationis, vol. 28, no. 4, pp. 40–49, 2005. View at Google Scholar · View at Scopus
  33. M. Tadrous, J. J. Gagne, T. Stürmer, and S. M. Cadarette, “Disease risk score as a confounder summary method: systematic review and recommendations,” Pharmacoepidemiology and Drug Safety, vol. 22, no. 2, pp. 122–129, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Strauss, “On miettinen's multivariate confounder score,” Journal of Clinical Epidemiology, vol. 51, no. 3, pp. 233–236, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Villar, H. E. Knight, M. de Onis et al., “Conceptual issues related to the construction of prescriptive standards for the evaluation of postnatal growth of preterm infants,” Archives of Disease in Childhood, vol. 95, no. 12, pp. 1034–1038, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Beck, D. Wojdyla, L. Say et al., “The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity,” Bulletin of the World Health Organization, vol. 88, no. 1, pp. 31–38, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Y. Chen, H. J. Ribaudo, S. Souda et al., “Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in botswana,” Journal of Infectious Diseases, vol. 206, no. 11, pp. 1695–1705, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. K. van der Merwe, R. Hoffman, V. Black, M. Chersich, A. Coovadia, and H. Rees, “Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study,” Journal of the International AIDS Society, vol. 14, no. 1, article 42, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Villar, L. Cheikh Ismail, C. G. Victora et al., “International standards for newborn weight, length, and head circumference by gestational age and sex: the newborn cross-sectional study of the intergrowth-21st project,” The Lancet, vol. 384, no. 9946, pp. 857–868, 2014. View at Publisher · View at Google Scholar
  40. L. F. Johnson, K. Stinson, M.-L. Newell et al., “The contribution of maternal HIV seroconversion during late pregnancy and breastfeeding to mother-to-child transmission of HIV,” Journal of Acquired Immune Deficiency Syndromes, vol. 59, no. 4, pp. 417–425, 2012. View at Publisher · View at Google Scholar · View at Scopus